A practical reference on Preclinical research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-03. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Other companies operating in Turin are Maserati, Lancia, Alfa Romeo, Iveco, Pininfarina, Bertone, Sparco, Italdesign Giugiaro, New Holland, Comau, Magneti Marelli, Graziano Oerlikon, Ghia, Fioravanti (automotive), Rai (national broadcasting company), Banca Investis, FCA Bank, Intesa Sanpaolo, Reale Mutua (finance), Invicta, Kappa, Superga (fashion), Ferrero, Lavazza, Martini & Rossi (food & beverage), Alpitour (hospitality and tourism), TILab (ex-CSELT), and Aurora (pen manufacturer). The city is also well known for its aerospace industry Alenia Aeronautica, Thales Alenia Space and Avio. The International Space Station modules Harmony, Columbus, Tranquility, as well as the Cupola and all MPLMs were produced in Turin. The future European launcher projects beyond Ariane 5 will also be managed from Turin by the new NGL company, a subsidiary of EADS (70%) and Aircraft Division of Leonardo (30%).
== Biosafety == Xenobiological systems are designed to convey orthogonality to natural biological systems. A (still hypothetical) organism that uses XNA, different base pairs and polymerases and has an altered genetic code will hardly be able to interact with natural forms of life on the genetic level. Thus, these xenobiological organisms represent a genetic enclave that cannot exchange information with natural cells. Altering the genetic machinery of the cell leads to semantic containment. In analogy to information processing in IT, this safety concept is termed a "genetic firewall". The concept of the genetic firewall seems to overcome a number of limitations of previous safety systems. A first experimental evidence of the theoretical concept of the genetic firewall was achieved in 2013 with the construction of a genomically recoded organism (GRO). In this GRO all known UAG stop codons in E.coli were replaced by UAA codons, which allowed for the deletion of release factor 1 and reassignment of UAG translation function. The GRO exhibited increased resistance to T7 bacteriophage, thus showing that alternative genetic codes do reduce genetic compatibility. This GRO, however, is still very similar to its natural "parent" and cannot be regarded to have a genetic firewall. The possibility of reassigning the function of large number of triplets opens the perspective to have strains that combine XNA, novel base pairs, new genetic codes, etc. that cannot exchange any information with the natural biological world.
A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Monoclonal antibodies are identical and can thus have monovalent affinity, binding only to a particular epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal antibodies are mixtures of antibodies derived from multiple plasma cell lineages which each bind to their particular target epitope. Artificial antibodies known as bispecific monoclonal antibodies can also be engineered which include two different antigen binding sites (FABs) on the same antibody. It is possible to produce monoclonal antibodies that specifically bind to almost any suitable substance; they can then serve to detect or purify it. This capability has become an investigative tool in biochemistry, molecular biology, and medicine. Monoclonal antibodies are used in the diagnosis of illnesses such as cancer and infections and are used therapeutically in the treatment of e.g. cancer and inflammatory diseases.
=== Heart disease === There is less evidence available for the optimal transfusion threshold for people with heart disease, including those who are having a heart attack. Guidelines recommend a higher threshold for people with heart disease of 80 g/L (8 g/dL) if they are not undergoing cardiac surgery.
Sources: en.wikipedia.org
== External links == Fankhauser's Page on Rennet history and use Appendix D - Assessment of filamentous fungi - Qualified Presumption of Safety FDA-registration of recombinant chymosin Recombinant Chymosin Cheese Yield Experiments and Proteolysis by Milk-Clotting Enzymes Validation of recombinant and bovine chymosin by mass spectrometry Native and Biotechnologically Engineered Plant Proteases with Industrial Applications
Although the mechanism of this reaction has not been fully elucidated, it is speculated that the use of an electron-deficient phosphonate accelerates elimination of the oxaphosphatane intermediate. This renders the initial addition of the phosphonate-stabilized carbanion to the aldehyde effectively irreversible, leading to Z-selectivity in analogy to the standard Wittig reaction.
Maureen Vevers. Chair of Governors, Askham Bryan College, York. For services to Further Education. Alexandra Ellen Vincent. Lately Chief Operating Officer, Arts and Humanities Research Council. For services to Research Funding. Suman Vohra. Vice Chair, Edinburgh Hindu Mandir and Cultural Centre. For services to the community in Edinburgh. Belinda Alison Voos. Lately Nurse Consultant in Paediatric Neurosurgery, Great Ormond Street Hospital for Children NHS Foundation Trust. For services to Paediatric Neurosurgical Nursing. Dorothy Helen Wagstaff. Founder, CASCAID. For services to Charity. David Walker. Chair of Trustees, Horizons Specialist Academy Trust. For services to Education. Susan Walker. Chief Commissioner, Girlguiding Scotland. For services to Young People. David Wallace. Senior Fleet Staff Engineer, Royal National Lifeboat Institution. For voluntary service to Maritime Safety. Lady (Julia Elizabeth) Walport (Dr. Julia Neild). Lately Trustee, The Amber Trust and Trustee, Ealing Youth Orchestra. For services to Young People and to Charity. Keith Norman Walton. Founder, Severnside Community Rail Partnership. For services to Urban Rail Transport in Bristol. John Ward. Chair, Charles and Elsie Sykes Trust. For services to Charity and to the community in Harrogate, North Yorkshire. Pamela Joan Ward. For services to the community in Whipsnade, Bedfordshire. William John Ward. For services to the community in the New Forest, Hampshire. Edward Charles Warner. Disability and Access Ambassador, Cabinet Office Disability Unit. For services to Disabled People.
== Awards == 2025 Fellow of the American Society for Mass Spectrometry 2024 The Analytical Scientist The Power List - Instrumental Innovators 2023 The Analytical Scientist The Power List - Innovators and Trailblazers 2022 American Society for Mass Spectrometry Biemann Medal 2022 International Mass Spectrometry Foundation Curt Brunnée Award 2021–2022 North Carolina State University Faculty Scholar 2021 The Analytical Scientist The Power List 2021 North Carolina State University Impact Scholars 2019 The Analytical Scientist The Power List 2017 Women Chemists Committee of the American Chemical Society Rising Star Award
is the fraction of all possible contacts that involves an infectious and susceptible individual. (This is mathematically similar to the law of mass action in chemistry in which random collisions between molecules result in a chemical reaction and the fractional rate is proportional to the concentration of the two reactants.) Between I and R, the transition rate is assumed to be proportional to the number of infectious individuals which is
Sources: en.wikipedia.org
Three whales die after the pod of about 30 whales re-stranded at Pūponga Beach in Golden Bay despite efforts to refloat them. 20 January – A second pod of about 11 whales is stranded near Taupata Point in the Golden Bay. 21 January – DOC staff and volunteers succeed in refloating the initial pod of 30 whales and ten whales from the second pod. One of the whales from the second pod dies. 22 January: Ten whales are re-stranded in Golden Bay, prompting a response from DOC and volunteers. The Body Shop NZ goes into voluntary administration. Media company NZME announces plans to cut 14 reporting and 24 production jobs as part of a restructuring process. 23 January: DOC staff, Project Jonah and community volunteers succeed in refloating the ten stranded whales in Golden Bay. Prime Minister Luxon gives his State of the Nation address. He announces that the existing Crown Research Institutes will be merged into three new Public Research Organisations and that the Government will establish a new foreign investment agency. 25 January – A tornado and severe storm hits Mangawhai and surrounding areas, causing two serious injuries, damage to about 50 properties and power outages affecting 4,700 homes. 27 January: In order to attract digital nomads, a 'digital nomad' visa is announced to allow non-residents to work in New Zealand for up to nine months, given they work entirely remotely for a non-New Zealand company. The work will be untaxed for up to 90 days.
== Science and technology == Caldwell 18 (NGC 185), a dwarf spheroidal galaxy of the Local Group in the constellation Cassiopeia Carbon-18 (C-18 or 18C), an isotope of carbon C18, the molecular formula of cyclo(18)carbon C18, an octadecyl-type hydrocarbon with 18 carbon atoms, such as Fatty acids such as Stearic acid, C18H36O2 Oleic acid C18H34O2 C18 bonded silica stationary phase column, a type of reversed-phase chromatography column IEC 60320 C18, a power connector Colorectal cancer (ICD-10 code) ISO/IEC 9899:2018 standard for the programming language C, informally named C18
=== Structural superposition === The most basic possible comparison between protein structures makes no attempt to align the input structures and requires a precalculated alignment as input to determine which of the residues in the sequence are intended to be considered in the RMSD calculation. Structural superposition is commonly used to compare multiple conformations of the same protein (in which case no alignment is necessary, since the sequences are the same) and to evaluate the quality of alignments produced using only sequence information between two or more sequences whose structures are known. This method traditionally uses a simple least-squares fitting algorithm, in which the optimal rotations and translations are found by minimizing the sum of the squared distances among all structures in the superposition. More recently, maximum likelihood and Bayesian methods have greatly increased the accuracy of the estimated rotations, translations, and covariance matrices for the superposition. Algorithms based on multidimensional rotations and modified quaternions have been developed to identify topological relationships between protein structures without the need for a predetermined alignment. Such algorithms have successfully identified canonical folds such as the four-helix bundle. The SuperPose Archived 2015-10-31 at the Wayback Machine method is sufficiently extensible to correct for relative domain rotations and other structural pitfalls.
Ultraviolet light detectors, fixed or variable wavelength, which includes diode array detectors. The ultraviolet light absorption of the effluent is continuously measured at single or multiple wavelengths. These are by far most popular detectors for liquid chromatography. Fluorescence detector. Irradiates the effluent with a light of set wavelength and measure the fluorescence of the effluent at a single or multiple wavelength. Refractive index detector. Continuously measures the refractive index of the effluent. The lowest sensitivity of all detectors. Often used in size exclusion chromatography for polymer analysis. Radio flow detector. Measures radioactivity of the effluent. This detector can be destructive if a scintillation cocktail is continuously added to the effluent. Chiral detector continuously measures the optical angle of rotation of the effluent. It is used only when chiral compounds are being analyzed. Conductivity monitor. Continuously measures the conductivity of the effluent. Used only when conductive eluents (water or alcohols) are used. Non-destructive detectors in gas chromatography:
Instant baby food – dehydrated baby food was produced by Gerber and Heinz in the 1980s. Dehydrated baby food products produced by both companies consisted of dehydrated food flakes. The Gerber product never came to fruition as a widely used product; it was only test-run in Omaha, Nebraska, for around eight to nine months, and consumer adoption was not sufficient for the product to go into mass production. Pablum Bird's Custard Camping food Condensed soup Powdered eggs Instant gravy – Bisto is a brand of powdered instant gravy that has been produced and consumed in Great Britain since 1908. Instant mashed potatoes Smash – a brand of Instant mashed potatoes in the United Kingdom Instant noodles Cup noodle List of instant noodle brands Instant oatmeal – Quaker Instant Oatmeal is an example Instant pudding Instant porridge – an example is Cream of Wheat brand, which includes an instant variety in its product line Instant rice Minute Rice – an instant rice brand Instant curry S&B Foods – an instant curry brand Instant soup Cup-a-Soup Portable soup Instant sauce mixes Instant tofu powder – introduced and produced circa 1966 by Japan Protein Industry (Nihon Tanpaku Kogyo), it was used at that time as a time-saver for the production of tofu. Later in 1973, a brand of instant tofu powder named Hausu Hontôfu was produced and marketed to consumers by the Hausu Foods Company.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.